Cargando…
LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
PURPOSE: Human epidermal growth factor receptor 3 (HER3) has been identified as an important component of many receptor tyrosine kinase-driven cancers. LJM716 is a human IgG monoclonal antibody that binds HER3, trapping it in an inactive conformation. In this study, a phase I dose escalation was per...
Autores principales: | Takahashi, Shunji, Kobayashi, Takayuki, Tomomatsu, Junichi, Ito, Yoshinori, Oda, Hisanobu, Kajitani, Tatsuhiro, Kakizume, Tomoyuki, Tajima, Takeshi, Takeuchi, Hiromi, Maacke, Heiko, Esaki, Taito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225197/ https://www.ncbi.nlm.nih.gov/pubmed/27942917 http://dx.doi.org/10.1007/s00280-016-3214-4 |
Ejemplares similares
-
A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
por: Reynolds, Kerry Lynn, et al.
Publicado: (2017) -
LJM Acknowledges its Reviewers
por: Bakoush, Omran
Publicado: (2015) -
Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors
por: Esaki, Taito, et al.
Publicado: (2019) -
Fungal Planet description sheets: 716–784
por: Crous, P.W., et al.
Publicado: (2018) -
716. A Case of Symptomatic Intestinal Spirochetosis
por: Chan, Zhi En, et al.
Publicado: (2020)